NCT00788125: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors |
|
|
| Terminated | 1/2 | 7 | US | carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy | City of Hope Medical Center, National Cancer Institute (NCI) | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific | 04/10 | 07/22 | | |
ChiCTR1800020096: A prospective, multi-center, single-arm clinical study for the efficacy and safety of dasatinib in the treatment of patients with unsuccessful imatinib desmoid tumor therapy. |
|
|
| Not yet recruiting | N/A | 51 | | pharmacotherapy 50mg/2 times/d | Peking University Cancer Hospital; Peking University Cancer Hospital, ChiaTai Tian Qqing Pharmaceutical Group Co., Ltd.(CTTQ) | Desmoid Tumor | | | | |
NCT05751733: Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
|
|
| Recruiting | N/A | 258 | RoW | Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib | Xiangya Hospital of Central South University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Gastrointestinal Stromal Tumors | 01/26 | 01/27 | | |
